The Hadassah Cancer Research Center (HCRC) is a center of academic excellence for the development of exceptional and cutting-edge treatments for cancer. Our close connection to patients at Hadassah hospital allows us to carry out high standard research focused on the needs of cancer patients.
Established in 2020, the HCRC advances cancer translational research in unique and innovative directions, including an emphasis on next-generation immunotherapy and cancer in three dimetions (levels): tissue, patient, and time (patient follow up).
The HCRC builds on the expertise and clinical knowledge of Hadassah clinicians, who are also first-rate scientists, guiding and supporting academia and the biomedical industry.
Under the direction of Prof. Michal Lotem, a leader in the field of immunotherapy, the HCRC offers state-of-the-art assays to evaluate the efficacy of anti-cancer treatments, enabled by immediate access to human tissue samples and Good Manufacturing Procedure-level infrastructures
Highly experienced scientists and lab personnel perform in vitro and in vivo tests that provide clinically- relevant insights into efficacy, mechanisms, and safety of antineoplastic therapies, thereby bridging the gap between bench and bedside.
The HCRC has built-in interphase to the oncology Early phase clinical trials unit, which allows the quick and simple transition of promising therapies to the clinic.